EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus

Agnieszka Mikłosz iD, Adrian Chabowski

The Journal of Clinical Endocrinology & Metabolism · 14.07.2023 · 108 (8) · 1889-1897

DOI: 10.1210/clinem/dgad142 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 14.03.2023. Verfasst von Agnieszka Mikłosz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Medical University of Bialystok, 15-222 Bialystok, Poland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Adipose Tissue, Mesenchymal Stem Cells. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science Center, Medical University of Bialystok.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The worldwide increase in the prevalence of diabetes mellitus has raised the demand for new therapeutic strategies targeting diabetic symptoms and its chronic complications. Among different treatment options for diabetes, adipose-derived mesenchymal stem cells (ADMSCs) therapy attract the most attention. The therapeutic effects of ADMSCs are based primarily on their paracrine release of immunomodulatory, anti-inflammatory, and trophic factors. Animal models of diabetes as well as human clinical trials have shown that ADMSCs can effectively facilitate endogenous β cell regeneration, preserve residual β cell mass, reduce islet graft rejection, regulate the immune system, and ultimately improve insulin sensitivity or ameliorate insulin resistance in peripheral tissues. Nevertheless, transplantation of mesenchymal stem cells is associated with certain risks; therefore recently much attention has been devoted to ADMSCs derivatives, such as exosomes or conditioned media, as therapeutic agents for the treatment of diabetes. Compared to ADMSCs, cell-free therapy has even better therapeutic potential. This narrative review summarizes recent outcomes and molecular mechanisms of ADMSCs action in the treatment for both type 1 DM and type 2 DM, as well as shows their feasibility, benefits, and current limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes MellitusAdipose TissueMesenchymal Stem CellsHumansInsulin Resistance

Stichwörter der Autor:innen

ADMSCsadipose-derived mesenchymal stem cellsinsulin resistanceinsulin secretionpancreatic β-cellstype 1 diabetes mellitustype 2 diabetes mellitus

Autor:innen und Institutionen

  • Department of Physiology, Medical University of Bialystok, 15-222 Bialystok, Poland.

ORCID-Profile: Agnieszka Mikłosz

Förderung

  • National Science Center
  • Medical University of Bialystok

Zitieren

APA

Mikłosz, A., & Chabowski, A. (2023). Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism, 108(8), 1889-1897. https://doi.org/10.1210/clinem/dgad142

Vancouver

Mikłosz A, Chabowski A. Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism. 2023;108(8):1889-1897. doi:10.1210/clinem/dgad142

BibTeX
@article{Mikosz2023,
  author = {Mikłosz, Agnieszka and Chabowski, Adrian},
  title = {Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {8},
  pages = {1889--1897},
  doi = {10.1210/clinem/dgad142}
}
Kostenlos starten →